Literature DB >> 16784007

Rhinitis medicamentosa.

J T Ramey1, E Bailen, R F Lockey.   

Abstract

Rhinitis medicamentosa (RM) is a condition induced by overuse of nasal decongestants. The term RM, also called rebound or chemical rhinitis, is also used to describe the adverse nasal congestion that develops after using medications other than topical decongestants. Such medications include oral beta-adrenoceptor antagonists, antipsychotics, oral contraceptives, and antihypertensives. However, there are differences in the mechanism through which congestion is caused by topical nasal decongestants and oral medications. Very few prospective studies of RM have been performed and most of the knowledge about the condition comes from case reports and histologic studies. Histologic changes consistent with RM include nasociliary loss, squamous cell metaplasia, epithelial edema, epithelial cell denudation, goblet cell hyperplasia, increased expression of the epidermal growth factor receptor, and inflammatory cell infiltration. Since the cumulative dose of nasal decongestants or time period needed to initiate RM has not been conclusively determined, these medications should only be used for the shortest period necessary. Validated criteria need to be developed for better diagnosis of the condition. Stopping the nasal decongestant is the first-line treatment for RM. If necessary, intranasal glucocorticosteroids should be used to speed recovery.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16784007

Source DB:  PubMed          Journal:  J Investig Allergol Clin Immunol        ISSN: 1018-9068            Impact factor:   4.333


  21 in total

Review 1.  Rhinitis medicamentosa: what an otolaryngologist needs to know.

Authors:  Jayesh Doshi
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-12-19       Impact factor: 2.503

2.  Systemic side effects of locally used oxymetazoline.

Authors:  Recep Dokuyucu; Hasan Gokce; Mustafa Sahan; Fatih Sefil; Zeynel Abidin Tas; Okan Tutuk; Atakan Ozturk; Cemil Tumer; Cengiz Cevik
Journal:  Int J Clin Exp Med       Date:  2015-02-15

3.  Potential toxicity of topical ocular solutions.

Authors:  Nevio Cimolai
Journal:  CMAJ       Date:  2019-08-12       Impact factor: 8.262

4.  Xylitol treats nasal mucosa in rhinitis medicamentosa: an experimental rat model study.

Authors:  Behram Cam; Murat Sari; Ahmet Midi; Ozgül Gergin
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-08-29       Impact factor: 2.503

5.  Peak nasal inspiratory flow: a useful and handy tool for the diagnosis of nasal obstruction in the elderly.

Authors:  Giancarlo Ottaviano; Valerie J Lund; Ennio Nardello; Bruno Scarpa; Ioannis Mylonakis; Giuliana Frasson; Valentina Iacono; Enzo Manzato; Gino Marioni; Alberto Staffieri
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-01-01       Impact factor: 2.503

6.  Advances in understanding and managing rosacea: part 2: the central role, evaluation, and medical management of diffuse and persistent facial erythema of rosacea.

Authors:  James Q Del Rosso
Journal:  J Clin Aesthet Dermatol       Date:  2012-03

7.  Treatment of congestion in upper respiratory diseases.

Authors:  Eli O Meltzer; Fernan Caballero; Leonard M Fromer; John H Krouse; Glenis Scadding
Journal:  Int J Gen Med       Date:  2010-04-08

8.  Pathophysiology of nasal congestion.

Authors:  Robert M Naclerio; Claus Bachert; James N Baraniuk
Journal:  Int J Gen Med       Date:  2010-04-08

9.  [Immunocytochemical detection of caspase 3 in various diseases of human nasal mucosa].

Authors:  R Hirt; F Paulsen; K Neumann; S Knipping
Journal:  HNO       Date:  2009-05       Impact factor: 1.284

Review 10.  Dermatological Adverse Events Associated with Topical Brimonidine Gel 0.33% in Subjects with Erythema of Rosacea: A Retrospective Review of Clinical Studies.

Authors:  Anna D Holmes; Kimberly A Waite; Michael C Chen; Kiruthi Palaniswamy; Thomas H Wiser; Zoe D Draelos; Elyse S Rafal; W Philip Werschler; Alison E Harvey
Journal:  J Clin Aesthet Dermatol       Date:  2015-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.